CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $34.95 ($6,990,000)
- 4 Grant or award Director acquired 405 shares (grant or award)
- 4 Grant or award Director acquired 543 shares (grant or award)
- 4 Grant or award Director acquired 775 shares (grant or award)
- 4 Shares withheld for taxes CEO gave up 76,171 shares (to pay taxes)
- 4 Planned sale Director sold 10,000 shares at $34.90 ($349,000)
- 4 Shares withheld for taxes President and Vant Chair gave up 40,310 shares (to pay taxes)
- 4 Shares withheld for taxes President & CIO gave up 46,878 shares (to pay taxes)
- 4 Planned sale Director sold 17,750 shares at an average $34.38 ($610,252)
- 4 Open-market sale Director sold 1,638,163 shares at an average $34.46 ($56,444,076)
- 4 Open-market sale Director sold 1,438,163 shares at an average $34.32 ($49,354,076)
- 4 Open-market sale Director by Deputization sold 1,438,163 shares at an average $34.32 ($49,354,076)
- 4 Open-market sale President & CIO sold 1,000,000 shares at an average $34.11 ($34,105,000)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at an average $33.16 ($6,631,268)
- 4 Shares withheld for taxes CFO gave up 2,129 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Accounting Officer gave up 3,582 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $30.27 ($6,054,000)
- 4 Shares withheld for taxes CFO gave up 18,962 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $29.59 ($5,918,000)
- 4 Grant or award CFO acquired 60,644 shares (grant or award)
Page 3 of 26 · 511 filings